Toronto, Ontario--(Newsfile Corp. - December 13, 2018) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, announced that it will makes its first issuance of shares under its online marketing and awareness program with AGORA Internet Relations Corp. ("AGORACOM"). The Company initially announced the online marketing and awareness program in its press release dated November 8, 2018.

Under this first share issuance, the Company will issue 226,000 common shares of the Company ("Shares"), representing a price of $0.05 per Share, for services valued at $10,000 plus 13% HST that have been provided by AGORACOM to date.

The Company also confirmed that it will be issuing an aggregate of a further $40,000 worth of Shares, plus HST, for further services provided. These additional Shares will be issued in $10,000 allotments at the completion of each three month period ending March 10, 2019, June 10, 2019, September 10, 2019 and December 31, 2019. The number of Shares to be issued at the end of each period will be determined by using the closing price of the Shares on the TSX Venture Exchange on the first trading day following each period for which the services were provided by AGORACOM.

To learn more about CardioComm's products and for further updates regarding HeartCheck™ ECG device integrations please visit the Company's websites at www.cardiocommsolutions.com and www.theheartcheck.com.

About AGORACOM

AGORACOM is the pioneer of online investor relations, online conferences and online marketing / branding services to North American small and mid-cap public companies, with more than 250 companies served. More than just lip service, AGORACOM is the home of more than 808K investors that visited 5.6 million times and read 52.4 million pages of information every year (Average 2008 - 2015).

AGORACOM traffic ranks within the top 0.5% of all websites around the world. These traffic results are independently tracked and verified by Google analytics. AGORACOM traffic can be attributed to its strategy of maintaining the cleanest, moderated small-cap discussion as a result of implementing the first ever Investor Controlled Stock Discussion Forums.

AGORACOM Founder, George Tsiolis, publishes the leading blog on small & mid cap investor relations. His 50 Small-Cap CEO Lessons are a must read for CEOs looking to increase their education and knowledge about online investor relations.

About CardioComm Solutions

CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).

FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
egrima@cardiocommsolutions.com
investor.relations@cardiocommsolutions.com

Forward-looking statements
This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.